Vanda Pharmaceuticals receives negative opinion from CHMP on Fanaptum Vanda Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Product for Human Use, or CHMP, has issued a negative opinion recommending against approval of Fanaptum for the treatment of schizophrenia in adult patients in the European Union. The CHMP was of the opinion that the benefits of Fanaptum did not outweigh its risks and recommended against marketing authorization at this point in time. Vanda intends to appeal this opinion and request a re-examination of the decision by the CHMP.
News For VNDA From The Last 14 Days
Check below for free stories on VNDA the last two weeks.
Vanda pullback a buying opportunity, says Piper Jaffray Piper Jaffray recommends using the post-earnings pullback in shares of Vanda Pharmaceuticals as a buying opportunity. Piper says Hetlioz is launching well and that it sees no reason to back off its bullish stance or $25 price target. The firm reiterates an Overweight rating on the name.